Selective type 1b MET inhibitor. It displays marked antitumor activity in MET-dependent tumor models. It crosses the blood-brain barrier and displays intracranial antitumor activity. Teptotinib can overcome EGFR inhibitor resistance mediated by aberrant c-Met activation and is in clinical use...
Know who made it. See the evidence. Buy through one marketplace.
Selective type 1b MET inhibitor. It displays marked antitumor activity in MET-dependent tumor models. It crosses the blood-brain barrier and displays intracranial antitumor activity. Teptotinib can overcome EGFR inhibitor resistance mediated by aberrant c-Met activation and is in clinical use for non-small cell lung cancer harboring MET exon 14 skipping alterations
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
MET identifies MET proto-oncogene, receptor tyrosine kinase in Homo sapiens (Human). This target record connects NCBI Gene 4233, UniProtKB P08581 and related ABMIUM catalogue products.
Biological function: Hepatocyte growth factor receptor (MET; c-MET/HGFR) is a receptor tyrosine kinase activated by hepatocyte growth factor. MET signalling regulates cell survival, proliferation, motility, morphogenesis and invasive growth.
